[O17] Oral Session 17　Hepatobiliary / Pancreatic Cancer
【E】

[O17-3] Pemigatinib (PEMI) for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202

^○Makoto Ueno¹, Ghassan K. Abou-Alfa^2,3, Vaibhav Sahai⁴, Antoine Hollebecque⁵, Gina Vaccaro⁶, Davide Melisi⁷, Raed Al-Rajabi⁸, Andrew Scott Paulson⁹, Mitesh J. Borad¹⁰, David Gallinson¹¹, Adrian G. Murphy¹², Do-Youn Oh¹³, Efrat Dotan¹⁴, Daniel V. Catenacci¹⁵, Eric Van Cutsem¹⁶, Christine Lihou¹⁷, Huiling Zhen¹⁷, Luis Féliz¹⁸, Arndt Vogel¹⁹ (1.Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, 2.Department of Medicine, Memorial Sloan Kettering Cancer Center, 3.Weill Medical College at Cornell University, 4.Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, 5.Department of Adult Medicine, Gustave Roussy, 6.Providence Cancer Center Oncology and Hematology Care Clinic, 7.Digestive Molecular Clinical Oncology Research Unit, Department of Medicine, Università degli studi di Verona, 8.Department of Internal Medicine, Division of Hematology/Oncology, University of Kansas Cancer Center, 9.Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, 10.Department of Internal Medicine, Mayo Clinic Cancer Center, 11.Department of Hematology/Oncology, Morristown Memorial Hospital, Carol Cancer Center, 12.Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 13.Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 14.Department of Hematology/Oncology, Fox Chase Cancer Center, 15.Department of Medicine, University of Chicago Medicine, 16.Department of Digestive Oncology, University Hospitals Leuven and KU Leuven, 17.Incyte Corporation, 18.Incyte Biosciences International Sàrl, 19.Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School)